Spasmo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spasmo

What is Spasmo? A Foundational Overview

Property Description
Active ingredient Hyoscine Butylbromide (INN)
Form Tablet (Oral), Injection Solution (Parenteral)
Pharmacological class Antispasmodic (Spasmolytic Agent)
Common use Relief of acute visceral muscle spasm
Origin Synthetic derivative of scopolamine

Spasmo: An Antispasmodic Agent

Spasmo is a pharmaceutical product defined by its active component, Hyoscine Butylbromide, which establishes its classification as an effective antispasmodic, or spasmolytic agent. Its primary purpose is to address pain resulting from acute, involuntary contractions of smooth muscle tissue. The compound is recognized as an anticholinergic antispasmodic.

The active core is a synthetic derivative of the naturally occurring belladonna alkaloid scopolamine. This origin and chemical modification are utilized for enhancing the therapeutic specificity of the compound, differentiating it from general analgesics. In a typical use scenario, such as a painful abdominal cramp, the medicine provides focused relief by targeting the underlying spasm itself.


Composition and Forms: Defining the Active Ingredient

The composition of Spasmo relies on Hyoscine Butylbromide as the single active ingredient, identifying it chemically as a quaternary ammonium compound. This structure results in low systemic absorption from the gastrointestinal tract and limits its ability to cross the blood-brain barrier.

The product is provided in various dosage forms, notably the common tablet for oral administration and a sterile injection solution intended for parenteral delivery. These distinct pharmaceutical preparations ensure flexibility in managing spasms, with the oral form typically positioned for managing general acute spasms.


How Hyoscine Butylbromide Provides Relief

The general therapeutic purpose of the medicine is to provide relief by achieving the inhibition of smooth muscle contraction within visceral organs. It operates as a selective peripheral anticholinergic, a mechanism that works by blocking the nerve signals responsible for triggering the painful tightening of muscles in the gastrointestinal, biliary, and urogenital tracts. This focused interruption relaxes the cramped muscle, thereby resolving the source of the visceral pain associated with the acute spasm.

What side effects are possible with Spasmo?

Possible Side Effects and Safety Information

The safety profile for Hyoscine Butylbromide (Spasmo) is characterized by effects resulting from its anticholinergic properties, which primarily manifest in the peripheral body systems. The official regulatory documents classify adverse reactions based on frequency of occurrence.

Frequency-Classified Adverse Reactions

Frequency Category Documented Adverse Reactions
Common (up to 1 in 10) Accommodation disorders (blurred vision), Tachycardia (increased heart rate), Dry mouth
Rare (up to 1 in 1,000) Urinary retention (inability to pass water)
Not Known (post-marketing) Anaphylactic shock (including fatal outcomes), Hypotension, Increased intraocular pressure, Mydriasis, Skin reactions (e.g., rash)

Serious Reactions and Safety Constraints

Serious adverse reactions are officially documented, most notably anaphylactic shock and severe hypotension, particularly associated with the injectable form. The risk of acutely increasing intraocular pressure is also noted, which necessitates caution.

Safety constraints exist for specific patient groups. The medicine is contraindicated in individuals with untreated narrow angle glaucoma due to the risk of elevated intraocular pressure. Caution is also noted for patients with pre-existing cardiac conditions (such as coronary heart disease or hypertension) because of the potential for increased heart rate and decreased blood pressure. Additionally, due to insufficient data, use during pregnancy and breastfeeding is generally not recommended by regulatory authorities. The quaternary ammonium structure of the compound restricts its ability to enter the central nervous system, generally limiting side effects to the periphery.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Spasmo (Hyoscine Butylbromide) is primarily characterized by documented manifestations of peripheral anticholinergic toxicity. These signs include an accelerated heart rate (tachycardia), dry mouth, urinary retention, reddening of the skin (flushing), inhibition of gastrointestinal motility, and transient visual disturbances, such as mydriasis. Severe, life-threatening outcomes reported in regulatory documents include respiratory paralysis and a serious respiratory pattern known as Cheynes-Stokes respiration.

For patients with underlying cardiac disease, parenteral administration has been associated with severe cardiac complications in regulatory alerts. The official management approach for these symptoms involves the administration of parasympathomimetic agents, such as Neostigmine, which is documented to reverse the anticholinergic effects. Supportive procedures may include gastric lavage and the use of activated charcoal for managing oral poisoning, or catheterisation to address urinary retention.

Urgent medical attention must be sought if unexplained, severe abdominal pain persists or if the pain is accompanied by symptoms defined in regulatory guidance, including fever, vomiting, fainting, decreased blood pressure, or the presence of blood in stool. Furthermore, urgent ophthalmological evaluation is required if a painful, red eye with loss of vision occurs.

Therapeutic Uses of Spasmo

Quick Facts: Uses of Spasmo

  • Acute Pain: Used for the management of moderate to moderately severe acute pain.
  • Muscle Spasms: Employed to address muscle spasms and associated discomfort in the abdominal area.
  • Colicky Pain: Indicated for relief in certain instances of sharp, localized pain, such as colicky pain.

What Spasmo Treats: Main Uses and Benefits

Spasmo is a prescription treatment utilized for the management of moderate to moderately severe acute pain. The therapeutic goal is to support the reduction of pain intensity and associated discomfort.

This medication is specifically employed to address symptoms related to involuntary contractions of smooth muscles, which can present as abdominal pain and cramping. Its action focuses on providing relief from muscle spasms, particularly those occurring within the gastrointestinal tract and related systems. Conditions that may involve this kind of sudden, localized pain, sometimes referred to as colicky pain, are among the indications for its use.

Spasmo is an option within a broader treatment plan for managing acute pain episodes and supporting patient comfort. It may also be used to help manage acute pain following certain surgical procedures. The treatment is intended to address the underlying pain symptoms.

Eligibility and Restrictions for Use

Absolute Contraindications

Spasmo (Hyoscine Butylbromide) must not be used by populations with specific pre-existing conditions where its anticholinergic properties could cause harm. Absolute prohibition is required for patients diagnosed with narrow-angle glaucoma, myasthenia gravis, and conditions involving the obstruction or paralysis of the gastrointestinal tract, such as megacolon or obstructive ileus. Use is also strictly contraindicated in individuals with urinary retention due to prostatic enlargement, or a known hypersensitivity to the active ingredient.


Restricted and Conditional Use

Use is officially not recommended for women who are pregnant or breastfeeding due to limited or insufficient data regarding effects on the fetus or infant. The oral tablet formulation is generally not recommended for children under 6 years of age.

Increased caution is mandatory when administering Spasmo to populations susceptible to tachyarrhythmia or those with underlying cardiac insufficiency. Caution is also required for patients with severe hepatic or renal impairment, and for older adults.

What should I know about interactions with other medicines?

The official regulatory profile for Hyoscine Butylbromide is defined by pharmacodynamic effects and specific administration constraints documented in government labeling.

Additive Pharmacodynamic Effects

Co-administration with medicines that possess anticholinergic activity may result in the intensification of effects. This documented class includes tricyclic and tetracyclic antidepressants, certain antihistamines, antipsychotic medicines (such as phenothiazines), and antiarrhythmics like quinidine and disopyramide. Other anticholinergics and Amantadine are also officially noted to contribute to these additive effects.

Opposing and Cardiovascular Effects

Combining the medicine with dopamine antagonists, such as metoclopramide, may result in the diminution of the effects of both drugs on gastrointestinal tract motility. The chronotropic action of beta-adrenergic agents (beta-agonists) is also documented to be enhanced.

Timing and Absorption Interference

Oral administration is subject to physical absorption interference. Antacids and adsorbent anti-diarrheals may reduce the medicine's absorption. Regulatory information dictates that the medicine must be administered at least one hour before these preparations.

Formal Restrictions

The intramuscular injection of this medicine is formally contraindicated in patients being treated with anticoagulant drugs, due to the documented risk of forming a localized intramuscular haematoma. Regulatory documents also include an explicit substance restriction advising against the consumption of alcohol during use.

Mechanism of Action

Spasmo functions as a selective antagonist of the M3 muscarinic acetylcholine receptors ( M3). These receptors are primarily located on the smooth muscle cells within target tissues. Upon binding to the M3 receptor, Spasmo prevents the natural neurotransmitter, acetylcholine, from activating the site. This blockade inhibits the downstream Gq-protein signaling pathway that normally leads to the activation of phospholipase C (PLC). PLC inhibition prevents the subsequent hydrolysis of PIP2 into IP3 and DAG. Consequently, the IP3-mediated release of intracellular calcium ( Ca^2+) from the sarcoplasmic reticulum is suppressed. The reduced Ca^2+ availability within the cytoplasm significantly diminishes the formation of the actin-myosin complex required for muscle contraction. This molecular cascade results in the direct relaxation and reduction of contractile activity in the smooth muscle tissue.

Dosage and Administration Information

Administration Routes and Standard Dosing

Spasmo (Hyoscine Butylbromide) is administered via two primary methods: the oral route using tablets and the parenteral route using an injection solution. The oral form, typically a 10 mg tablet, is used for general application. The standard adult oral dosing ranges from 10 mg to 20 mg per dose, which may be repeated up to three to four times daily. Oral tablets should be swallowed whole with water and may be taken with or without food.


Parenteral Use and Specific Conditions

For more immediate needs, the medicine is available as an injectable solution (typically 20 mg/mL) which can be given as a slow intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection. The standard parenteral dose for adults is 20 mg to 40 mg, and the total daily dose is limited to 100 mg. Procedural constraints require the IV injection to be administered slowly. Furthermore, for patients receiving anticoagulant therapy, the IV or SC route is utilized instead of IM injection.


Duration and Population-Specific Rules

The medicine is utilized for the symptomatic relief of acute episodes of spasm and is not recommended for continuous, long-term daily administration. For pediatric patients aged 6 to 12 years, the oral dosing regimen is 10 mg administered three times daily. This frequency and duration framework defines the specific usage pattern for the treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Spasmo

Evidence for use in Stomach and Intestine Cramps

This section will summarize the types of clinical studies available that have investigated the use of Spasmo to explore patterns related to spasms or cramps in the stomach and intestines, detailing the nature and size of the patient groups studied.

Research has examined Spasmo for use in conditions characterized by fluctuating or episodic manifestations related to the digestive system. These studies primarily focused on outcomes related to physical discomfort and how they were measured in the digestive tract. The evidence often involves clinical trials where patients with acute or disruptive episodes were monitored over defined time intervals to observe patterns in outcomes related to physical discomfort.

The findings describe patterns observed in the studies where Spasmo was associated with changes in patient-reported outcomes describing perceived discomfort. Specifically, research suggests patterns related to the intensity and duration of episodes relevant in trials assessing short-term or episodic symptom patterns.

However, evidence is limited regarding whether these patterns hold true across all causes of stomach and intestine discomfort. Findings were mixed in some research scenarios, and it is clear that results apply only to the populations studied. More comprehensive research is needed to contribute to understanding short-term changes across different types of episodic discomfort.


Evidence for use in Irritable Bowel Syndrome (IBS) Symptoms

This part will describe the research studies that have evaluated patterns related to Spasmo and common symptoms associated with Irritable Bowel Syndrome (IBS), such as abdominal pain and discomfort, and explain the key findings summarized from these trials.

Spasmo was evaluated in studies involving individuals with Irritable Bowel Syndrome, a condition marked by functional limitations and cycles of stability and flare-ups. This research applied in studies examining patient-reported experiences of symptoms like abdominal pain and bloating, which are outcomes reflecting daily functioning or activity level. Research explored patterns related to the frequent, fluctuating or unstable symptoms of IBS.


Long-term Studies and Follow-up

This section will summarize what is known about the patterns observed during Spasmo research over extended periods, outlining the findings from studies with long-term follow-up and discussing the main gaps in data regarding very long-term outcomes.

Research involving long-term follow-up for Spasmo is generally characterized by several research limitation frames. While Spasmo was studied in research exploring short-term symptom changes, the information regarding long-term patterns beyond a few weeks or months is often constrained. Studies that monitored patients for longer periods often had sample sizes were modest, meaning the results are based on a smaller number of people.


Evidence in Special Populations

This section will outline what specific studies have been conducted to evaluate Spasmo in particular patient groups, such as older adults or individuals with coexisting medical conditions, where the evidence may be more limited or warrants special consideration.

Evidence for Spasmo in various special populations is often limited. While Spasmo was observed in general adult patient groups, dedicated research that accounts for the specific characteristics of different demographics is less frequent. Data for certain groups remain insufficient.


What is still uncertain about Spasmo

This final section will synthesize the main evidence gaps, highlighting areas where research findings are inconsistent or where studies are lacking, and clarifying the key questions that still need to be addressed by future research on Spasmo.

Despite the available evidence, several key areas of uncertainty remain. The evidence highlights what is known—and what is still uncertain. For instance, while some research suggests specific patterns, findings were mixed in other research scenarios, and research is ongoing to clarify these differences. A major gap is the lack of robust, long-term evidence, as discussed above.

Frequently Asked Questions (FAQ)

Common questions about Spasmo (FAQ)

Q: What is Spasmo primarily used for besides the main condition?

According to official product information, Spasmo (hyoscine butylbromide) is indicated for the relief of painful spasms in the smooth muscles of the gastrointestinal (stomach and intestines) and genito-urinary (kidneys, bladder, etc.) tracts. It is also often used for the symptomatic relief of cramping associated with Irritable Bowel Syndrome (IBS).


Q: How quickly should I expect Spasmo to start working after taking it?

The onset of effect can vary among individuals. Regulatory data shows that peak concentration of the drug in the plasma is typically reached about two hours after taking an oral tablet. However, since the medicine acts locally on the smooth muscle in the gut, the clinical relief from spasms may be felt sooner than this.


Q: Does Spasmo make you feel tired or drowsy?

Spasmo is designed to act mainly on the peripheral nervous system, which means it is generally not expected to cause sedation. However, rare adverse effects such as dizziness or accommodation disorders (problems focusing vision) have been reported, which could potentially impair the ability to drive or operate machinery. Observing caution is generally recommended.


Q: Is it normal to feel a little dizzy when first starting Spasmo?

Yes, official documentation lists dizziness as a common adverse effect, which can occur with the tablets or injection. If any adverse effects, like dizziness, become severe or persistent, the product label advises seeking medical attention.


Q: What is the difference between Spasmo and a regular over-the-counter painkiller?

Spasmo is classified as an antispasmodic, working primarily to relax the smooth muscles responsible for cramps by blocking specific receptors in the digestive and urinary tracts. Regular over-the-counter painkillers (like NSAIDs), on the other hand, primarily reduce pain and inflammation and do not directly target muscle spasms in the same way.


Q: Can Spasmo interact with common cold or flu medications?

Yes, Spasmo can interact with other medicines that have anticholinergic properties, such as certain antihistamines found in some cold and flu remedies. Combining these may lead to additive effects, potentially increasing the risk of side effects like dry mouth, constipation, or blurred vision.


Q: How long does the effect of a single dose of Spasmo typically last?

The symptomatic action of a single dose generally lasts for several hours. Official information indicates the action generally lasts for several hours.


Q: Do people take Spasmo for stomach cramps or just muscle spasms?

Spasmo is indicated for the relief of both: smooth muscle spasms and the associated cramping pain. Its official uses cover both the gastrointestinal tract (stomach and bowel cramps) and the genito-urinary tract.


Q: Is Spasmo safe to take for older adults?

Regulatory documents suggest that caution may be appropriate for older adults, particularly those who have underlying health conditions. This is because official warnings advise caution in patients susceptible to intestinal or urinary outlet obstructions (like prostatic enlargement) and certain cardiac conditions, which are more common in the elderly population.


Q: Are there any known foods or drinks that should be avoided while on Spasmo?

While the product literature does not typically list specific food interactions, official product information suggests that caution regarding alcohol consumption may be necessary. Alcohol can potentially increase the chance of certain side effects, such as drowsiness.


Q: Does Spasmo have a long-term effect, or is it only for immediate relief?

Spasmo is intended for the immediate, symptomatic relief of acute episodes of spasm. It is not recommended for continuous, long-term daily administration. For symptoms that require continuous, long-term daily treatment, official guidance states a medical investigation should be sought.


Q: Is Spasmo known to cause stomach upset or nausea?

Spasmo is generally used to relieve abdominal discomfort. Official product guidance advises that severe, unexplained abdominal pain that persists or worsens requires prompt medical investigation, as such symptoms could indicate a serious underlying condition.


Q: Why is Spasmo sometimes prescribed instead of other spasm-treating drugs?

Spasmo is a quaternary ammonium derivative with a localized antispasmodic action, primarily targeting the smooth muscle of the digestive and urinary tracts. Its chemical structure is designed to limit entry into the central nervous system (CNS), distinguishing its action from certain other drug classes.


Q: Can Spasmo affect my ability to concentrate during the day?

Yes, regulatory safety information states that side effects like blurred vision (accommodation disorders) or dizziness may occur. These effects could temporarily impair concentration and the ability to perform skilled tasks.


Q: Is it okay to drive while taking Spasmo?

Official product information advises that caution should be observed regarding driving or operating machinery. This is because side effects such as accommodation disorders or dizziness have been reported, which may affect reaction time.


Q: What are the signs that Spasmo is actually working for my condition?

Since Spasmo is a symptomatic relief medication, the main sign that it is working would be a reduction or resolution of the painful muscle spasms and cramping. If pain and symptoms do not improve or worsen, regulatory guidance suggests the condition may require reassessment.


Q: Can Spasmo be used by people who have mild kidney problems?

The oral form is poorly absorbed into the systemic circulation and is largely eliminated via the faeces. Due to this elimination profile, official data suggests that significant dose adjustments or problems are generally not required for patients with mild to moderate kidney impairment.


Q: What happens if I forget to take a dose of Spasmo?

The patient information leaflet typically advises against taking a double dose to compensate for a missed dose and recommends continuing with the next scheduled dose.


Q: Are there any common side effects of Spasmo that usually go away after a few days?

Common anticholinergic side effects include dry mouth, blurred vision, and dizziness. While generally described as mild, the regulatory documents do not specify which side effects will definitely resolve after only a few days.


Q: Does Spasmo help with nerve pain or just muscle issues?

Spasmo works by exerting a spasmolytic action, which relaxes the smooth muscles in the gastrointestinal and genito-urinary tracts. It does not have an approved indication or primary mechanism of action for the treatment of nerve pain.


Q: Can women take Spasmo while they are breastfeeding?

Regulatory information advises caution during breastfeeding. While information suggests low levels may pass into breast milk, the product label states that the baby may need to be monitored for potential effects like sleepiness or constipation.


Q: What if Spasmo doesn't seem to be working after a week?

If symptoms, especially severe, unexplained abdominal pain, persist or worsen, or do not show improvement within 48 hours of starting treatment, medical advice should be sought immediately to investigate the cause of the symptoms.


Q: Is it true that Spasmo can cause dry mouth?

Yes, dry mouth (xerostomia) is a commonly reported side effect. This occurs because the drug has anticholinergic properties, which can reduce saliva production.


Q: How does Spasmo actually work to stop muscle spasms?

Spasmo stops spasms by blocking muscarinic receptors on smooth muscle cells in the digestive and urinary tracts. This action inhibits the function of a natural chemical called acetylcholine, causing the smooth muscles to relax and relieving the spasm.


Q: What populations is Spasmo typically not recommended for?

The drug is contraindicated (not recommended) for patients with untreated narrow-angle glaucoma, an enlarged prostate that causes urinary retention, mechanical blockage in the gut, myasthenia gravis, and megacolon, among other conditions.


Q: What are the main benefits people report from taking Spasmo?

The intended benefit, as listed in the indications, is the rapid relief of painful smooth muscle spasms and cramping in the abdominal area. This helps manage acute episodes related to the gut, bladder, or kidney tracts.


Q: Does Spasmo have any interactions with herbal teas or remedies?

The product label does not cover interactions with all herbal remedies. However, caution is advised regarding the use of Spasmo with any product, including herbal ones, that has known anticholinergic activity, as this may increase the risk of side effects.


Q: Can Spasmo affect blood pressure readings?

Yes, decreased blood pressure (hypotension) has been reported as an adverse effect, particularly when the medicine is administered by injection. Official guidance suggests that patients with cardiac conditions may require monitoring.


Q: Is Spasmo a prescription-only medication?

The prescription status of Spasmo (hyoscine butylbromide) varies by region. In many countries, the oral form for specific uses like Irritable Bowel Syndrome is available over-the-counter, while the injectable form typically requires a prescription.


Q: Why do doctors often combine Spasmo with other therapies?

Spasmo's primary function is to relieve muscle spasm—a symptom. Therefore, healthcare providers may combine it with other medications that target the underlying cause of the pain or condition, offering comprehensive symptomatic relief.


Q: Is Spasmo commonly used for tension headaches?

The approved indications for Spasmo are specific to the painful spasms of the gastrointestinal and genito-urinary tracts. Its use for conditions like tension headaches is not listed on the official product label.


Q: How long does Spasmo stay in your system after the last dose?

Based on pharmacokinetic data, the terminal elimination half-life for the active compound has been reported to be between 6.2 and 10.6 hours. This means it takes approximately five half-lives for the drug to be largely cleared from the body.


Q: What are the major contraindications for using Spasmo?

Major contraindications include untreated narrow-angle glaucoma, prostate hypertrophy with urinary retention, mechanical stenosis of the GI tract, tachycardia, and myasthenia gravis, among others.


Q: Are there any known interactions between Spasmo and alcoholic beverages?

Official product information notes that alcohol consumption may increase the chance of experiencing side effects, such as drowsiness. Therefore, caution is advised.


Q: Does Spasmo require any special monitoring while being taken?

Special monitoring may be required, particularly when the injectable form of Spasmo is used in patients with cardiac conditions. This is due to the potential for adverse effects like a fast heart rate (tachycardia) or low blood pressure (hypotension).


Q: Is it safe to suddenly stop taking Spasmo?

Since Spasmo is an acute, as-needed medication, the patient information states that there is typically no need to continue taking the tablets once the pain and spasms have resolved. The drug is not associated with dependency issues upon discontinuation.


Q: Why is Spasmo sometimes called an antispasmodic?

It is referred to as an antispasmodic because its primary function, as described in the pharmacodynamic properties, is to exert a spasmolytic action. This means it relieves or prevents the involuntary spasms of the smooth muscle tissue.


Q: Are there common signs of an allergic reaction to Spasmo?

Signs of hypersensitivity or an allergic reaction, as per official documentation, can include skin reactions (like rash or hives) and difficulty breathing (dyspnoea). Swelling of the face, lips, or tongue are also signs that require prompt medical attention.


Q: Are there different generic versions of Spasmo?

Spasmo is a trade name for the active ingredient hyoscine butylbromide. This active ingredient is widely available globally under various generic names and different branded formulations, as listed by regulatory agencies in various regions.


Q: Is Spasmo effective for period cramps in women?

The drug is officially indicated for spasms of the genito-urinary tract, which includes the uterus. The active ingredient, hyoscine butylbromide, is commonly recognized and used in many jurisdictions for the treatment of menstrual cramps.


Q: What are the differences between Spasmo and typical muscle relaxants?

Spasmo is a peripherally acting antispasmodic that specifically targets and relaxes the smooth muscles in organs like the gut and bladder. Typical muscle relaxants often act on the central nervous system to relieve spasms in skeletal (voluntary) muscles, representing a different class of action.

How should Spasmo be stored and disposed of?

How to Store and Dispose of Spasmo (Hyoscine Butylbromide)

The official labeling for Spasmo dictates specific mandatory storage conditions to maintain the product's stability and efficacy.

Storage Requirements

Condition Requirement
Temperature Store below 30 C; some formulations specify below 25 C.
Protection Keep in the original outer carton to protect the medicine from light.
Child Safety The medicine must be kept out of the sight and reach of children.
Stability Do not use the product after the expiry date. Injectable solutions must be used immediately after opening the ampoule and any remainder discarded.

Disposal Instructions

Unused or expired Hyoscine Butylbromide must be managed as pharmaceutical waste. Do not dispose of the medicine via wastewater or household waste. Consult a pharmacist for instructions on proper disposal in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spasmo found in:

A-Z Index: